Sort
130,381 grants matching “hiv”
Liposomal Amphotericin B and Flucytosine Antifungal Strategies for Talaromycosis (LAmB-FAST)
$1,326,630Thuy Le · Duke University · R01 · FY2024 · AI
Preclinical Development of HIV-1 Vif Antagonists
$1,326,345Mario Stevenson · Univ Of Massachusetts Med Sch Worcester · U19 · FY2008 · MH
Southern Consortium Node of the Clinical Trials Network
$1,326,149Kathleen Theresa Brady · Medical University Of South Carolina · U10 · FY2011 · DA
The International URBAN Alcohol Research Collaboration on HIV/AIDS (ARCH) Center
$1,325,994Jeffrey H Samet · Boston Medical Center · P01 · FY2022 · AA
Retroviral Replication and Vector Design
$1,325,896Stephen H Hughes · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Expanding and Increasing Access to HIV and AIDS Treatment and Care
$1,325,864William C Philbrick · Care Usa · U2G · FY2008 · PS
Pediatric Clinical Research Scholar Program - Washington
$1,325,793Children'S Research Institute · K12 · FY2005 · RR
Clinical optimization of a tenofovir enema and adherence tracking
$1,325,694Craig Walter Hendrix · Johns Hopkins University · U19 · FY2017 · AI
Clinical Trials of Patients with AIDS-Related Malignancies
$1,325,644Robert Yarchoan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
HIV persistence in vivo
$1,325,455Eli Boritz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
CENTER FOR AIDS RESEARCH
$1,325,241University Of Pennsylvania · P30 · FY2000 · AI
TRANZANIA AIDS PREV PROJECT: HIV RISK REDUCTION & CARE & TREATMENT OF DURG USERS
$1,325,000Gad Paul Kilonzo · Muhimbili University/ Allied Hlth Scis · U2G · FY2011 · PS
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
$1,324,786Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · UM1 · FY2022 · AI
Administrative Core
$1,324,541Wesley Ian Sundquist · University Of Utah · P50 · FY2020 · AI
Expertise in Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines: Blocker Discovery
$1,324,494Peter Silvera · Advanced Bioscience Laboratories, Inc. · N01 · FY2024 · AI
PS10-1001, HIV PREVENTION PROJECTS
$1,324,012Sandra L Knocke · Nebraska St Dept Of Health & Human Servs · U62 · FY2010 · PS
TEXAS REPOSITORY FOR AIDS NEUROPATHOGENESIS RESEARCH
$1,323,951University Of Texas Medical Br Galveston · R24 · FY2000 · MH
Targeting ensembles of Drug Resistant HIV Proteases
$1,323,553Univ Of Massachusetts Med Sch Worcester · P01 · FY2004 · GM
Development of Ultra Long-Acting Oral HIV Therapies
$1,323,542Andrew Martin Bellinger · Lyndra Therapeutics, Inc. · R01 · FY2017 · AI
Development of Ultra Long-Acting Oral HIV Therapies
$1,323,542Andrew Martin Bellinger · Lyndra Therapeutics, Inc. · R01 · FY2018 · AI
Development of Ultra Long-Acting Oral HIV Therapies
$1,323,542Andrew Martin Bellinger · Lyndra Therapeutics, Inc. · R01 · FY2019 · AI
Gut Homing Cells in SIV infection
$1,323,534Aftab A. Ansari · Emory University · R01 · FY2012 · AI
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM IN AIDS
$1,323,311Donna Mildvan · Beth Israel Medical Ctr (New York) · U01 · FY2006 · AI
THE NNTC COLLECTS, STORE, AND PROVIDE CLINICAL DATA AND WELL CHARACTERIZED BIOLOGICAL SPECIMENS, INCLUDING POST-MORTEM TISSUE FROM STUDY VOLUNTEERS AND/OR ORGAN DONORS WITH HIV AS WELL AS HIV-NEGATIVE
$1,323,215Vactor Hadijah · Icahn School Of Medicine At Mount Sinai · N01 · FY2023 · MH
Prevention Umbrella for MSM in the Americas
$1,323,041Susan Buchbinder · Public Health Foundation Enterprises · R01 · FY2011 · AI